Axsome Therapeutics, Inc. (AXSM) Financial Statements (2026 and earlier)

Company Profile

Business Address ONE WORLD TRADE CENTER, 29TH FLOOR
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments322,933325,272303,016300,910315,353327,341
Cash and cash equivalent322,933325,272303,016300,910315,353327,341
Receivables224,464196,507198,825161,398142,001124,096
Inventory, net of allowances, customer advances and progress billings27,93823,77418,44116,31915,73214,265
Inventory27,93823,77418,44116,31915,73214,265
Other undisclosed current assets13,65119,78916,33816,00711,97813,411
Total current assets:588,986565,342536,620494,634485,064479,113
Noncurrent Assets
Inventory, Noncurrent11,55511,86210,24110,97310,51810,500
Finance lease, right-of-use asset, after accumulated amortization6,6007,1005,7005,4004,3004,200
Operating lease, right-of-use asset20,85821,65422,47223,2945,3835,730
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization562605667773584683
Intangible asset, including goodwill, after accumulated amortization52,56154,16855,77557,36458,93660,543
Goodwill12,04212,04212,04212,04212,04212,042
Intangible asset, excluding goodwill, after accumulated amortization40,51942,12643,73345,32246,89448,501
Other undisclosed noncurrent assets8,6838,5198,3104,2333,713689
Total noncurrent assets:100,819103,908103,165102,03783,43482,345
TOTAL ASSETS:689,805669,250639,785596,671568,498561,458
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities260,768228,542237,048211,435186,634158,990
Accounts payable65,53754,22791,62885,65971,99764,253
Accrued liabilities195,231174,315145,420125,776114,63794,737
Debt72,54572,49772,0141,8161,4211,280
Business combination, contingent consideration, liability10,0129,6959,2328,6028,2858,131
Other undisclosed current liabilities35,51149,55623,80522,06133,76427,786
Total current liabilities:378,836360,290342,099243,914230,104196,187
Noncurrent Liabilities
Long-term debt and lease obligation121,952122,322121,332185,057183,653182,953
Long-term debt, excluding current maturities117,746117,642117,540181,377180,710180,002
Finance lease, liability4,2064,6803,7923,6802,9432,951
Liabilities, other than long-term debt100,722112,911103,279114,49597,72689,420
Operating lease, liability23,18223,04123,62423,9056,0466,440
Business combination, contingent consideration, liability77,54089,87079,65590,59091,68082,980
Total noncurrent liabilities:222,674235,233224,611299,552281,379272,373
Total liabilities:601,510595,523566,710543,466511,483468,560
Equity
Equity, attributable to parent88,29573,72773,07553,20557,01592,898
Common stock555555
Additional paid in capital1,394,2511,351,1241,303,2431,235,4001,179,7971,140,768
Accumulated deficit(1,305,961)(1,277,402)(1,230,173)(1,182,200)(1,122,787)(1,047,875)
Total equity:88,29573,72773,07553,20557,01592,898
TOTAL LIABILITIES AND EQUITY:689,805669,250639,785596,671568,498561,458

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues195,999170,992150,042121,463118,766104,762
Cost of revenue(7,367)(24,413)(13,448)(10,889)(21,162)(24,504)
Cost of product and service sold (11,912)(13,448)(9,789)(10,514)(8,437)
Gross profit:188,632146,579136,594110,57497,60480,258
Operating expenses(218,062)(192,688)(181,410)(167,556)(170,221)(142,882)
Other undisclosed operating income 2,473 8,102   
Operating loss:(26,957)(46,109)(36,714)(56,982)(72,617)(62,624)